Fundraising Fox
Gracellbio
Suzhou, CN · 10 known investors
Find your way into Gracellbio
Each arrow is one introduction. Sign up to fill in the first one.
Ask Jianwei Yuan to introduce you to Wei (William) Cao
You →Jianwei · together at 6 Dimensions Capital →Wei
Sign up to find every way you can get introduced to Gracellbio
- Your email: who you already know at Gracellbio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Gracellbio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases. The company operates manufacturing facilities in China and was acquired by AstraZeneca in February 2024.
Founders & leadership
Investors · 10
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Pivotal Life Sciences's portfolio page · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
Frequently asked questions
- What does Gracellbio do?
- Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases. The company operates manufacturing facilities in China and was acquired by AstraZeneca in February 2024.
- Who founded Gracellbio?
- Gracellbio was founded by William Wei Cao.
- Who are Gracellbio's investors?
- Gracellbio's investors include LAV, Lilly Asia Ventures, OrbiMed, Pivotal Life Sciences, Exome Asset Management, Janus Henderson Investors, RA Capital, Temasek and 2 more.
- Where is Gracellbio headquartered?
- Gracellbio is headquartered in Suzhou, CN.